Clinical Trial Update: Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of CRS-207, a live-attenuated Listeria monocytogenes-based cancer vaccine, in adults with selected advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Adenocarcinoma

Drugs mentioned

• CRS-207

Snippet

Sponsor: Anza Therapeutics, Inc. | Conditions: Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas | Phase 1 | Status: TERMINATED